Articles
| Open Access |
DOI: Prevention & Treatment Of Cardiovascular Diseases
Dr. Imran Aslam , Department Of Pharmacology, Samarkand State Medical Institute, Samarkand, Uzbekistan Yuldashev Soatboy Jiyanboyevich , Department Of Pharmacology, Samarkand State Medical Institute, Samarkand, Uzbekistan Abdurakhmanova Zamira Ergashboevna , Department Of Pharmacology, Samarkand State Medical Institute, Samarkand, UzbekistanAbstract
Cardiovascular disease is a significant problem that humans have always faced, affecting thousands of people's lives and health and taking the lives of many people. Many medical institutions and researchers have regarded it as a significant problem in overcoming the cardiovascular disease.1 Much attention has been paid, so the prevention and treatment level in this area has also been rapidly improved. However, cardiovascular disease still cannot be prevented or treated fundamentally, and it is still a significant danger to human health. All people still hope for breakthrough results in cardiovascular disease.2 This article analyzes the prevention and treatment of cardiovascular diseases, and has obtained a series of practical and reliable conclusions.
Keywords
Prevention and treatment, Cardiovascular disease
References
Davies, S. W. (2001). Clinical presentation and diagnosis of coronary artery disease: stable angina. British medical bulletin, 59(1), 17-27.
Davies, S. W. (2001). Clinical presentation and diagnosis of coronary artery disease: stable angina. British medical bulletin, 59(1), 17-27.
Ghuran, A. V., & Camm, A. J. (2001). Ischaemic heart disease presenting as arrhythmias. British medical bulletin, 59(1), 193-210.
Bailey, R. L., Thuppal, S. V., Sherif, K. D., Denby, N., Steinbaum, S. R., Haycock, B., ... & von Schacky, C. (2019). No Relationship Between Serum 25 (OH) Vitamin D Concentrations and Perceptions of Vitamin D Dietary Intake Adequacy in US and German Adults Not Using Dietary Supplements. In Nutritional Influences on Bone Health (pp. 247-256). Springer, Cham.
Daull, P., Jeng, A. Y., & Battistini, B. (2007). Towards triple vasopeptidase inhibitors for the treatment of cardiovascular diseases. Journal of cardiovascular pharmacology, 50(3), 247-256.
Blanco-Colio, L. M. (2014). TWEAK/Fn14 axis: a promising target for the treatment of cardiovascular diseases. Frontiers in immunology, 5, 3.
DiNicolantonio, J. J., Liu, J., & O’Keefe, J. H. (2018). Magnesium for the prevention and treatment of cardiovascular disease.
Bale, J. R., Ryan, T. J., Reddy, K. S., & Howson, C. P. (Eds.). (1998). Control of cardiovascular diseases in developing countries: research, development, and institutional strengthening. National Academies Press.
Beaglehole, R., Saracci, R., & Panico, S. (2001). Cardiovascular diseases: causes, surveillance and prevention. International Journal of Epidemiology, 30(suppl_1), S1.
Prabhakaran, D., Jeemon, P., & Roy, A. (2016). Cardiovascular diseases in India: current epidemiology and future directions. Circulation, 133(16), 1605-1620.
Celermajer, D. S., Chow, C. K., Marijon, E., Anstey, N. M., & Woo, K. S. (2012). Cardiovascular disease in the developing world: prevalences, patterns, and the potential of early disease detection. Journal of the American College of Cardiology, 60(14), 1207-1216.
Mark, D. B., Van de Werf, F. J., Simes, R. J., White, H. D., Wallentin, L. C., Califf, R. M., & Armstrong, P. W. (2007). Cardiovascular disease on a global scale: defining the path forward for research and practice. European heart journal, 28(21), 2678-2684.
Hancock, S. L., Tucker, M. A., & Hoppe, R. T. (1993). Factors affecting late mortality from heart disease after treatment of Hodgkin's disease. Jama, 270(16), 1949-1955.
Fonarow, G. C., Gawlinski, A., Moughrabi, S., & Tillisch, J. H. (2001). Improved treatment of coronary heart disease by implementation of a Cardiac Hospitalization Atherosclerosis Management Program (CHAMP). The American journal of cardiology, 87(7), 819-822.
Collins, R., & MacMahon, S. (1994). Blood pressure, antihypertensive drug treatment and the risks of stroke and of coronary heart disease. British medical bulletin, 50(2), 272-298.
Rashkind, W. J. (1983). Transcatheter treatment of congenital heart disease. Circulation, 67(4), 711-716.
Capewell S, Allender S, Critchley J, Lloyd-Williams F, O'Flaherty M, Rayner M, et al. Modelling the UK burden of Cardiovascular Disease to 2020. London: Cardio and Vascular Coalition and the British Heart Foundation, 2008.
British Heart Foundation. Stroke and your heart. [cited 2014 4th September]; Available from: http://www.bhf.org.uk/hearthealth/conditions/stroke.aspx.
Levy D, Kannel WB. Cardiovascular risks: new insights from Framingham. American Heart Journal. 1988;116:266-72.
Reddy KS, Satija A. The Framingham Heart Study: impact on the prevention and control of cardiovascular diseases in India. Progress in cardiovascular diseases. 2010;53:21-7.
van den Hoogen PCW, Feskens EJM, Nagelkerke NJD, Menotti A, Nissinen A, Kromhout D. The relation between blood pressure and mortality due to coronary heart disease among men in different parts of the world. New England Journal of Medicine. 2000;342:1-8. 203
Rockhill B, Newman B, Weinberg C. Use and misuse of population attributable fractions. American Journal of Public Health. 1998;88(1):15-9.
Smulders YM, Thijs A, Twisk JW. New cardiovascular risk determinants do exist and are clinically useful. European heart journal. 2008;29:436-40.
Mackenbach JP, Cavelaars AEJM, Kunst AE, Groenhof F. Socioeconomic inequalities in cardiovascular disease mortality: an international study. European heart journal. 2000;21:1141-51.
DeWilde S, Carey IM, Richards N, Whincup PH, Cook DG. Trends in secondary prevention of ischaemic heart disease in the UK 1994-2005: use of individual and combination treatment. Heart. 2008;94:83-8.
Rose G. Rose's Strategy of Preventive Medicine. Oxford: Oxford University Press; 2008. 209 92. Rose G. Sick individuals and sick populations. International Journal of Epidemiology. 2001;30:427-32.
Di Castelnuovo A, Costanzo S, Bagnardi V, Donati MB, Iacoviello L, de Gaetano G. Alcohol dosing and total mortality in men and women: an updated meta-analysis of 34 prospective studies. Archives of Internal Medicine. 2006;166:2437-45.
Charlton BG. A critique of Geoffrey Rose's 'population strategy' for preventive medicine. Journal of the Royal Society of Medicine. 1995;88:607-10.
Burton H, Sagoo GS, Pharoah P, Zimmern RL. Time to revisit Geoffrey Rose: strategies for prevention in the genomic era? Italian Journal of Public Health. 2012;9(4):e8665.
Hingorani A, Hemingway H. How should we balance individual and population benefits of statins for preventing cardiovascular disease? BMJ. 2011;342:c6244.
Jackson R, Lynch J, Harper S. Preventing coronary heart disease. BMJ. 2006;332:617-8.
Cobiac LJ, Magnus A, Lim S, Barendregt JJ, Carter R, Vos T. Which interventions offer best value for money in primary prevention of cardiovascular disease? PLoS ONE. 2012;7(7):e41842.
Ebrahim S, Taylor F, Ward K, Beswick A, Burke M, Davey Smith G. Multiple risk factor interventions for primary prevention of coronary heart disease. Cochrane Database of Systematic Reviews. 2011;DOI: 10.1002/14651858.CD001561.pub3.
de Cates AN, Farr MRB, Wright N, Jarvis MC, Rees K, Ebrahim S, et al. Fixed-dose combination therapy for the prevention of cardiovascular disease. Cochrane Database of Systematic Reviews. 2014;DOI: 10.1002/14651858.CD009868.pub2.
Wald NJ, Law MR. A strategy to reduce cardiovascular disease by more than 80%. BMJ. 2003;326:1419-23. 149. Anderson KM, Odell PM, Wilson PW, Kannel WB. Cardiovascular disease risk profiles. Am Heart J. 1990;121:293-8.
Cooney MT, Cooney HC, Dudina A, Graham IM. Assessment of cardiovascular risk. Current hypertension reports. 2010;12:384-93.
Dent THS. Predicting the risk of coronary heart disease I. The use of conventional risk markers. Atherosclerosis. 2010;213:345-51.
Sheridan SL, Crespo E. Does the routine use of global coronary heart disease risk scores translate into clinical benefits or harms? A systematic review of the literature. BMC health services research. 2008;8:60
Leyland AH. Socioeconomic gradients in the prevalence of cardiovascular disease in Scotland: the roles of composition and context. Journal of Epidemiology and Community Health. 2005;59:799-803.
Pickett KE, Pearl M. Multilevel analyses of neighbourhood socioeconomic context and health outcomes: a critical review. Journal of Epidemiology and Community Health. 2001;55:111-22.
Stafford M, Bartley M, Mitchell R, Marmot M. Characteristics of individuals and characteristics of areas: investigating their influence on health in the Whitehall II study. Health and Place. 2001;7:117-29.
Barker DJP. The origins of the developmental origins theory. Journal of Internal Medicine. 2007;261:412-7. 188. Judge K, Bauld L. Learning from policy failure? Health Action Zones in England. European journal of public health. 2006;16(4):341-4.
Stafford M, Nazroo J, Popay JM, Whitehead M. Tackling inequalities in health: evaluating the New Deal for Communities initiative. Journal of Epidemiology and Community Health. 2008;62:298-304.
Article Statistics
Copyright License
Copyright (c) 2021 The American Journal of Medical Sciences and Pharmaceutical Research
This work is licensed under a Creative Commons Attribution 4.0 International License.
Authors retain the copyright of their manuscripts, and all Open Access articles are disseminated under the terms of the Creative Commons Attribution License 4.0 (CC-BY), which licenses unrestricted use, distribution, and reproduction in any medium, provided that the original work is appropriately cited. The use of general descriptive names, trade names, trademarks, and so forth in this publication, even if not specifically identified, does not imply that these names are not protected by the relevant laws and regulations.